129 related articles for article (PubMed ID: 35696556)
1. Expression and prognostic significance of chromatin modulators EHMT2/G9a and KDM2b in acute myeloid leukemia.
Gouda MBY; Zidane MA; Abdelhady AS; Hassan NM
J Cell Biochem; 2022 Aug; 123(8):1340-1355. PubMed ID: 35696556
[TBL] [Abstract][Full Text] [Related]
2. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
3. G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Neuromolecular Med; 2022 Dec; 24(4):392-398. PubMed ID: 35113321
[TBL] [Abstract][Full Text] [Related]
4. The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
Lehnertz B; Pabst C; Su L; Miller M; Liu F; Yi L; Zhang R; Krosl J; Yung E; Kirschner J; Rosten P; Underhill TM; Jin J; Hébert J; Sauvageau G; Humphries RK; Rossi FM
Genes Dev; 2014 Feb; 28(4):317-27. PubMed ID: 24532712
[TBL] [Abstract][Full Text] [Related]
5. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.
Park SE; Yi HJ; Suh N; Park YY; Koh JY; Jeong SY; Cho DH; Kim CS; Hwang JJ
Oncotarget; 2016 Jun; 7(26):39796-39808. PubMed ID: 27174920
[TBL] [Abstract][Full Text] [Related]
8. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
9. GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.
Alves-Silva JC; de Carvalho JL; Rabello DA; Serejo TRT; Rego EM; Neves FAR; Lucena-Araujo AR; Pittella-Silva F; Saldanha-Araujo F
Invest New Drugs; 2018 Oct; 36(5):955-960. PubMed ID: 29855824
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase G9a modulates hepatic insulin signaling via regulating HMGA1.
Xue W; Huang J; Chen H; Zhang Y; Zhu X; Li J; Zhang W; Yuan Y; Wang Y; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):338-346. PubMed ID: 29101051
[TBL] [Abstract][Full Text] [Related]
11. The lysine methyltransferase Ehmt2/G9a is dispensable for skeletal muscle development and regeneration.
Zhang RH; Judson RN; Liu DY; Kast J; Rossi FM
Skelet Muscle; 2016; 6():22. PubMed ID: 27239264
[TBL] [Abstract][Full Text] [Related]
12. EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Chen TQ; Hu N; Huo B; Masau JF; Yi X; Zhong XX; Chen YJ; Guo X; Zhu XH; Wei X; Jiang DS
Int J Biol Sci; 2020; 16(7):1252-1263. PubMed ID: 32174799
[TBL] [Abstract][Full Text] [Related]
13. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Silva-Carvalho AÉ; Alencar APD; Resende MR; da Costa DF; Nonino A; Neves FAR; Saldanha-Araujo F
Toxicol In Vitro; 2020 Dec; 69():104992. PubMed ID: 32889036
[TBL] [Abstract][Full Text] [Related]
15. Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage.
Ginjala V; Rodriguez-Colon L; Ganguly B; Gangidi P; Gallina P; Al-Hraishawi H; Kulkarni A; Tang J; Gheeya J; Simhadri S; Yao M; Xia B; Ganesan S
Sci Rep; 2017 Nov; 7(1):16613. PubMed ID: 29192276
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma.
Zhang J; Chen W; Ma W; Song K; Lee S; Han C; Wu T
Mol Cancer Res; 2022 Mar; 20(3):350-360. PubMed ID: 34880125
[TBL] [Abstract][Full Text] [Related]
17. EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS
Pribluda A; Daemen A; Lima AN; Wang X; Hafner M; Poon C; Modrusan Z; Katakam AK; Foreman O; Eastham J; Hung J; Haley B; Garcia JT; Jackson EL; Junttila MR
Elife; 2022 Aug; 11():. PubMed ID: 35983994
[TBL] [Abstract][Full Text] [Related]
18. Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy.
Papait R; Serio S; Pagiatakis C; Rusconi F; Carullo P; Mazzola M; Salvarani N; Miragoli M; Condorelli G
Circulation; 2017 Sep; 136(13):1233-1246. PubMed ID: 28778944
[TBL] [Abstract][Full Text] [Related]
19. EHMT2 (G9a) activation in mantle cell lymphoma and its associated DNA methylation and gene expression.
Wang J; Xu H; Ge S; Xue C; Li H; Jing X; Liang K; Zhang X; Zhang C
Cancer Biol Med; 2021 Oct; 19(6):836-49. PubMed ID: 34633777
[TBL] [Abstract][Full Text] [Related]
20. The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
Kim SK; Kim K; Ryu JW; Ryu TY; Lim JH; Oh JH; Min JK; Jung CR; Hamamoto R; Son MY; Kim DS; Cho HS
Int J Oncol; 2019 Jan; 54(1):65-76. PubMed ID: 30365075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
